A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov ID: NCT06667908

Public ClinicalTrials.gov record NCT06667908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Study identification

NCT ID: NCT06667908
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Enrollment: 130 participants

Conditions and interventions

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Concurrent Chemo/Radiation Therapy (cCRT) Radiation
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin Drug
Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel Drug
Durvalumab Biological
JNJ-90301900 Drug

Radiation · Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 5, 2024
Primary completion: Dec 30, 2028
Completion: Dec 30, 2028
Last update posted: Apr 13, 2026

2024 – 2028

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Connecticut Health Center	Farmington	Connecticut	06030	Recruiting
Yale University	New Haven	Connecticut	06519	Recruiting
University of Miami	Miami	Florida	33136	Recruiting
Orlando Health Cancer Institute	Orlando	Florida	32806	Recruiting
Emory University Winship Cancer Institute	Atlanta	Georgia	30306	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27514	Recruiting
FirstHealth of the Carolinas	Pinehurst	North Carolina	28374	Recruiting
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	Recruiting
Oregon Health And Science University	Portland	Oregon	97239	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Vermont Medical Center	Burlington	Vermont	05401	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06667908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2026 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06667908 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →